Skip to main content

Table 2 The relationship between CRC clinicopathological features and p16 exon 1/2 hypermethylation

From: The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging

Variables N p16 exon 1 hypermethylation (n; %) P-value p16 exon 2 hypermethylation (n; %) P-value
Negative Positive Negative Positive
Gender
 Female 12 6 (50%) 6 (50%) 1.000 8 (66.7%) 4 (33.3%) 0.264
 Male 18 10 (55.6%) 8 (45.4%) 7 (38.9%) 11 (61.1%)
Age
  ≤ 55 years 15 6 (40%) 9 (60%) 0.272 6 (40%) 9 (60%) 0.466
  > 55 years 15 10 (66.7%) 5 (33.3%) 9 (60%) 6 (40%)
Differentiation
 Low 6 1 (16.7%) 5 (83.3%) 0.072 1 (16.7%) 5 (83.3%) 0.169
 Moderate-High 24 15 (75%) 9 (25%) 14 (58.3%) 10 (41.7%)
pT stage
 pT1–2 8 6 (75%) 2 (25%) 0.226 7 (87.5%) 1 (12.5%) 0.035*
 pT3–4 22 10 (45.5%) 12 (54.5%) 8 (36.4%) 14 (63.6%)
pN stage
 pN0 13 10 (76.9%) 3 (23.1%) 0.033* 8 (61.5%) 5 (38.5%) 0.462
 pN1–2 17 6 (35.3%) 11 (64.7%) 7 (41.2%) 10 (58.8%)
Dukes stage
 A-B 13 10 (76.9%) 3 (23.1%) 0.033* 8 (61.5%) 5 (38.5%) 0.462
 C-D 17 6 (35.3%) 11 (64.7%) 7 (41.2%) 10 (58.8%)
  1. *Statistically significant